UNSPSC 51312508: Tiacrilast sodium

This classification denotes a histamine-1 receptor antagonist C12H9N2O3S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4PG8A6UTDX, chemically known as sodium (e)-6-(methylthio)-4-oxo-3(4h)-quinazolineacrylate, monohydrate, but more generally known as tiacrilast sodium, which bears US NIH Compound Identifier 23665632. Most nations, for tariff and trade purposes, schedule tiacrilast sodium under HS 29335995 and SITC 51576. As of Q4 2014, TIACRILAST SODIUM remains US FDA's Preferred Term for this commodity.

Tiacrilast sodium bears US NLM identifiers UMLS ID C2348786 and NCI Concept Code C72862. SMILES: CSC1CCC2C(C1)C(=O)N(CN2)/C=C/C(=O)[O-].O.[NA+].

UNSPSC 51312508 Tiacrilast sodium is a Commodity code that in practice captures state and local procurement of pharmaceutical products, including naloxone, generic multi-source drugs, and over-the-counter medications—reflecting the narrower scope of actual solicitations rather than the code's specific drug name. State and local health agencies, county health departments, and cooperative purchasing alliances are the primary issuing bodies, with purchases driven by public health and community health initiatives. The work involves sourcing pharmaceutical products through competitive bidding or RFP processes, with vendors required to meet FDA compliance, manufacturing practice certifications, supply chain security standards, and insurance requirements. Suppliers must often work through authorized wholesaler networks and maintain pricing flexibility across multiple formats, with contracts typically spanning two years with optional renewals.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 and quarterly deliveries to the county community health building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as an exploratory information-gathering effort regarding direct-to-manufacturer prescription programs aimed at improving efficiency in the state's pharmacy benefit program, with no formal competitive timeline yet established. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026; awarded vendors must be available through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and provide products by May 1, 2026, with contracts effective July 1, 2026.